Polymeric Nanoparticle Systems for Drug Delivery Applications

Polymeric nanoparticles have emerged as versatile carriers for the targeted and controlled delivery of therapeutic agents. Constructed from biodegradable and biocompatible polymers such as polylactic-co-glycolic acid (PLGA), chitosan, poly(ethylene glycol) and natural biopolymers, these colloidal systems range in size from 10 to 500 nm. Key advantages include enhanced solubility of poorly water-soluble drugs, prolonged circulation times, reduced systemic toxicity and the capacity for surface modification to achieve active targeting. Fabrication methods—emulsion–diffusion, nanoprecipitation, spray drying and microfluidics—allow precise control of particle size, morphology and drug loading. Surface functionalisation with ligands, antibodies or peptides affords receptor-mediated uptake by specific cell types, while stimuli-responsive designs exploit pH, temperature or enzyme triggers within the pathological microenvironment to release payloads on demand. Ongoing innovations address challenges in reproducibility, large-scale manufacture and long-term stability. These systems are under investigation across a spectrum of applications, including oncology, ophthalmology, central nervous system disorders and nutraceutical delivery. The global significance of polymeric nanoparticles lies in their potential to transform standard treatments into precision therapies, mitigate multidrug resistance and enhance patient compliance. As regulatory pathways evolve, translation of these nanomedicines into clinical practice will hinge on rigorous characterisation of pharmacokinetics, biodistribution and safety profiles.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Polymeric Nanoparticle Systems for Drug Delivery Applications publication trend

The graph below shows the total number of articles in polymeric nanoparticle systems for drug delivery applications across all publications each year (not limited to Nature Index journals).

Technical terms

Polymeric nanoparticle: A colloidal particle formed from synthetic or natural polymers, typically 10–500 nm in diameter, used to encapsulate and deliver drugs.

Surface functionalisation: The chemical or physical modification of nanoparticle surfaces with ligands, polymers or biomolecules to alter interactions with cells and biological fluids.

Stimuli-responsive release: Controlled drug discharge triggered by environmental cues such as pH, temperature, redox potential or specific enzymes.

Prodrug: An inactive or less active precursor molecule that undergoes in vivo transformation to release the active therapeutic agent.

Zeta potential: The electrical potential at the slipping plane of a nanoparticle, indicative of colloidal stability and surface charge.

Tumour microenvironment: The complex milieu surrounding cancer cells, including acidic pH, hypoxia, enzymes and stromal elements, which can be exploited for targeted drug release.

References

1. Transformable Neuropeptide Prodrug with Tumor Microenvironment Responsiveness for Tumor Growth and Metastasis Inhibition of Triple‐Negative Breast Cancer. Advanced Science (2023).
2. Surface Bio‐engineered Polymeric Nanoparticles. Small (2024).
3. Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors. Frontiers in Pharmacology (2021).
4. Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials (2020).